Novo Nordisk has laid out a new strategy aimed at addressing investor concerns while building on its dominance in obesity treatments. The company presented the plan at its capital markets day, signaling a dual focus on expanding its existing obesity franchise and broadening its pipeline beyond current therapeutic areas.
A key part of the strategy involves direct-to-consumer work, suggesting a push to reach patients more directly in the competitive weight-loss market. At the same time, Novo is seeking to diversify its drug development pipeline, a move designed to reduce reliance on any single product category.
The strategy comes as investors have been pressing the company to show how it will maintain growth amid rising competition and shifting market dynamics. By pairing obesity expansion with pipeline diversification, Novo is attempting to balance short-term momentum with long-term resilience.